Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manfred Kaufmann

Showing results (91-100 of 141) with videos related to

Pageof 15
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 13, 2006
CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93)Gunter von Minckwitz, Erika Graf, Matthias Geberth, et al.
Cancer|September 7, 2002
Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast and measurement of nitric oxide using electron paramagnetic resonance spectroscopySibylle Loibl, Gunter von Minckwitz, Sonja Weber, et al.
Carcinogenesis|March 13, 2009
Ceramide synthases and ceramide levels are increased in breast cancer tissueSusanne Schiffmann, Jessica Sandner, Kerstin Birod, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2009
Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer GroupWolfgang Eiermann, Erika Graf, Beyhan Ataseven, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer GroupManfred Kaufmann, Erika Graf, Walter Jonat, et al.
Gynecologic Oncology|September 11, 2010
Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumorsGünter Emons, Manfred Kaufmann, Grigor Gorchev, et al.
Breast Cancer Research : BCR|March 11, 2009
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancersAchim Rody, Uwe Holtrich, Laos Pusztai, et al.
European Journal of Cancer (Oxford, England : 1990)|September 28, 2007
A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93Manfred Kaufmann, Erika Graf, Walter Jonat, et al.
Oncology Reports|November 8, 2005
Demographic and psychosocial factors associated with risk perception for breast cancerUwe G Pöhls, Peter A Fasching, Heike Beck, et al.
The Journal of Biological Chemistry|August 25, 2005
Polo-like kinase 1-mediated phosphorylation stabilizes Pin1 by inhibiting its ubiquitination in human cellsFrank Eckerdt, Juping Yuan, Krishna Saxena, et al.
Pageof 15

Showing results (91-100 of 141) with videos related to

Sort By:
Pageof 15
European Journal of Cancer (Oxford, England : 1990)|June 13, 2006
CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93)Gunter von Minckwitz, Erika Graf, Matthias Geberth, et al.
Cancer|September 7, 2002
Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast and measurement of nitric oxide using electron paramagnetic resonance spectroscopySibylle Loibl, Gunter von Minckwitz, Sonja Weber, et al.
Carcinogenesis|March 13, 2009
Ceramide synthases and ceramide levels are increased in breast cancer tissueSusanne Schiffmann, Jessica Sandner, Kerstin Birod, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2009
Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer GroupWolfgang Eiermann, Erika Graf, Beyhan Ataseven, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer GroupManfred Kaufmann, Erika Graf, Walter Jonat, et al.
Gynecologic Oncology|September 11, 2010
Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumorsGünter Emons, Manfred Kaufmann, Grigor Gorchev, et al.
Breast Cancer Research : BCR|March 11, 2009
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancersAchim Rody, Uwe Holtrich, Laos Pusztai, et al.
European Journal of Cancer (Oxford, England : 1990)|September 28, 2007
A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93Manfred Kaufmann, Erika Graf, Walter Jonat, et al.
Oncology Reports|November 8, 2005
Demographic and psychosocial factors associated with risk perception for breast cancerUwe G Pöhls, Peter A Fasching, Heike Beck, et al.
The Journal of Biological Chemistry|August 25, 2005
Polo-like kinase 1-mediated phosphorylation stabilizes Pin1 by inhibiting its ubiquitination in human cellsFrank Eckerdt, Juping Yuan, Krishna Saxena, et al.
Pageof 15